Rankings
▼
Calendar
FULC Q1 2024 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
FULC
Fulcrum Therapeutics, Inc.
$436M
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
-100.0% YoY
Gross Profit
-$479,000
Operating Income
-$30M
Net Income
-$27M
EPS (Diluted)
$-0.43
QoQ Revenue Growth
-100.0%
Cash Flow
Operating Cash Flow
-$25M
Free Cash Flow
-$25M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$233M
Total Liabilities
$19M
Stockholders' Equity
$214M
Cash & Equivalents
$40M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$295,000
-100.0%
Gross Profit
-$479,000
-$16M
+97.1%
Operating Income
-$30M
-$28M
-6.8%
Net Income
-$27M
-$25M
-8.4%
← FY 2024
All Quarters
Q2 2024 →